About Antidote
Antidote is a company based in London (United Kingdom) founded in 2008 by Jessica Mann.. Antidote has raised $52 million across 5 funding rounds from investors including LBO France, Merck Global Health Innovation Fund and Smedvig Capital. The company has 39 employees as of December 31, 2023. Antidote offers products and services including Smart Match Search Engine and Precision Recruitment Services. Antidote operates in a competitive market with competitors including Evidation, myTomorrows, Dyania Health, SubjectWell and Clara Health, among others.
- Headquarter London, United Kingdom
- Employees 39 as on 31 Dec, 2023
- Founders Jessica Mann
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Antidote Technologies Ltd.
- Date of Incorporation 20 Apr, 2011
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
$10.68 M (USD)160as on Dec 31, 2021
-
Net Profit
-
EBITDA
$-2.08 M (USD)61as on Dec 31, 2021
-
Total Equity Funding
$52 M (USD)
in 5 rounds
-
Latest Funding Round
$23.2 M (USD), Series C
Jun 03, 2021
-
Investors
LBO France
& 5 more
-
Employee Count
39
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Antidote
Antidote offers a comprehensive portfolio of products and services, including Smart Match Search Engine and Precision Recruitment Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tool that helps patients find appropriate clinical trials quickly.
Services for sponsors to fill clinical trials faster and efficiently.
Unlock access to complete
Funding Insights of Antidote
Antidote has successfully raised a total of $52M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $23.2 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $23.2M
-
First Round
First Round
(25 Oct 2011)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2021 | Amount | Series C - Antidote | Valuation | LBO France | |
| Sep, 2017 | Amount | Series B - Antidote | Valuation | Merck Global Health Innovation Fund | |
| Feb, 2015 | Amount | Series B - Antidote | Valuation | Smedvig Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Antidote
Antidote has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include LBO France, Merck Global Health Innovation Fund and Smedvig Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are made in France and the US.
|
Founded Year | Domain | Location | |
|
Corporate-backed venture capital is focused on the life science sector.
|
Founded Year | Domain | Location | |
|
Investment in private equity and venture capital since 1996.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Antidote
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Antidote
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Antidote Comparisons
Competitors of Antidote
Antidote operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evidation, myTomorrows, Dyania Health, SubjectWell and Clara Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Real-world health data is provided for research and decisions.
|
|
| domain | founded_year | HQ Location |
Platform provides access to drugs in development to patients and physicians
|
|
| domain | founded_year | HQ Location |
Patients for clinical trials are identified through a dedicated platform.
|
|
| domain | founded_year | HQ Location |
Clinical trials marketplace for patient recruitment solutions is provided.
|
|
| domain | founded_year | HQ Location |
Clinical trials are matched to patients via an online platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Antidote
Frequently Asked Questions about Antidote
When was Antidote founded?
Antidote was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Where is Antidote located?
Antidote is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Antidote?
Nicole Anuszkiewicz Batiste is the current CEO of Antidote.
Is Antidote a funded company?
Antidote is a funded company, having raised a total of $52M across 5 funding rounds to date. The company's 1st funding round was a Series B of $13.5M, raised on Oct 25, 2011.
How many employees does Antidote have?
As of Dec 31, 2023, the latest employee count at Antidote is 39.
What is the annual revenue of Antidote?
Annual revenue of Antidote is $10.68M as on Dec 31, 2021.
What does Antidote do?
Antidote, earlier known as TrialReach, is a metasearch engine, helps patients to find and compare treatments in development and to connect them directly with the doctorsinvestigators carrying out the research. It also allows healthcare providers to put their patient data in their EMR into TrialReachs platform at scale, enabling groups of patients to be automatically matched to potentially suitable clinical trials.TrialReach is already working with leading health organizations, including the World Health Organization, and claims that three-quarters of the top twenty pharmaceutical companies are using its platform to support their clinical trials.
Who are the top competitors of Antidote?
Antidote's top competitors include Evidation, myTomorrows and Dyania Health.
What products or services does Antidote offer?
Antidote offers Smart Match Search Engine and Precision Recruitment Services.
Who are Antidote's investors?
Antidote has 6 investors. Key investors include LBO France, Merck Global Health Innovation Fund, Smedvig Capital, Octopus Ventures, and Amadeus Capital Partners.